Bolt Biotherapeutics Inc
NASDAQ:BOLT 1:00:00 PM EDT
| Market Cap (Intraday) | 11.35M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $5.84 |
| 50-Day MA | $6.45 |
| 200-Day MA | $9.58 |
Bolt Biotherapeutics Inc Stock, NASDAQ:BOLT
900 Chesapeake Drive, Redwood City, California 94063
United States of America
Phone: +1.650.665.9295
Number of Employees: 100
Description
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.